TY  - JOUR
ID  - discovery10187048
VL  - 122
Y1  - 2024/04//
N2  - The development and validation of non-invasive fibrosis tests (NITs) has changed clinical practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent liver disease in western countries, with up to a third of the unselected adult population affected. In this article, we review the use of NITs in the diagnosis and staging of MASLD. We discuss their use in the diagnosis of steatosis, steatohepatitis and fibrosis and critically evaluate recently published data. These NITs include a variety of approaches, such as serum markers like FIB-4, pro-C3 and ELF, imaging techniques like Fibroscan® and MRE, and combined scores like Agile 3+ and Agile 4, offering a range of options for healthcare providers. Furthermore, these non-invasive tests also serve as valuable prognostic tools, allowing for better risk assessment and improved patient management, particularly in predicting liver-related events and overall mortality.
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
JF  - European Journal of Internal Medicine
AV  - public
SP  - 11
A1  - Zoncapè, Mirko
A1  - Liguori, Antonio
A1  - Tsochatzis, Emmanuel A
KW  - NAFLD; Fibroscan; FIB4; ELF; Cirrhosis
EP  - 19
SN  - 0953-6205
UR  - http://dx.doi.org/10.1016/j.ejim.2024.01.013
PB  - Elsevier
TI  - Non-invasive testing and risk-stratification in patients with MASLD
ER  -